Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0079 | 0.3787 | 0.34 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0071 | 0.32 | 0.2776 |
Echinococcus granulosus | carboxylesterase 5A | 0.0157 | 1 | 1 |
Loa Loa (eye worm) | glutamate receptor | 0.0079 | 0.3787 | 0.3787 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0066 | 0.2774 | 0.2323 |
Echinococcus multilocularis | acetylcholinesterase | 0.0157 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0157 | 1 | 1 |
Echinococcus granulosus | metabotropic glutamate receptor 5 | 0.0097 | 0.523 | 0.3399 |
Echinococcus multilocularis | acetylcholinesterase | 0.0157 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0157 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0157 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0157 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0157 | 1 | 1 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0089 | 0.4643 | 0.4309 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.0097 | 0.523 | 0.3399 |
Loa Loa (eye worm) | hypothetical protein | 0.0097 | 0.523 | 0.523 |
Loa Loa (eye worm) | carboxylesterase | 0.0157 | 1 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0157 | 1 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0157 | 1 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0157 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = -11 % | DNDI: Inhibition of Human African Trypanosomiasis, SBRI 427, in vitro at 2 ug.mL-1 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.